Great Novel Therapeutics Biotech & Medicals

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

22

Website

www.gntbm.com.tw

Country

Taiwan

Exchange

Taipei Exchange

Great Novel Therapeutics Biotech & Medicals develops drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy

GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity.

It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.

Key Stats

52-Week Range

NT$28.45NT$82.80

Beta0.37

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-2.15

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.